EFG Asset Management (Americas)’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-1,530
Closed -$201K 139
2022
Q4
$201K Buy
+1,530
New +$198K 0.05% 129
2022
Q1
Sell
-1,525
Closed -$233K 137
2021
Q4
$233K Buy
1,525
+1
+0.1% +$155 0.04% 131
2021
Q3
$246K Buy
1,524
+1
+0.1% +$168 0.04% 135
2021
Q2
$249K Hold
1,523
0.05% 135
2021
Q1
$229K Buy
1,523
+1
+0.1% +$159 0.05% 133
2020
Q4
$231K Buy
1,522
+1
+0.1% +$143 0.05% 133
2020
Q3
$206K Buy
1,521
+1
+0.1% +$136 0.05% 136
2020
Q2
$208K Buy
+1,520
New +$194K 0.05% 121
2015
Q1
Sell
-1,200
Closed -$121K 179
2014
Q4
$121K Buy
+1,200
New +$117K 0.07% 117

Other funds holding IBB

EFG Asset Management (Americas)'s IBB Position: Q1 2023 in Review

EFG Asset Management (Americas) sold out of iShares Biotechnology ETF (IBB) in Q1 2023, closing a stake of 1,530 shares — an estimated $201K sold.

EFG Asset Management (Americas) first reported a position in IBB in Q4 2014 and held it in 9 quarters. The position peaked at $249K in Q2 2021. 866 funds tracked by Wall St. Rank hold IBB as of Q1 2023.

  • EFG Asset Management (Americas) reported no remaining iShares Biotechnology ETF position as of Q1 2023 after selling out during the quarter.
  • EFG Asset Management (Americas) sold 1,530 iShares Biotechnology ETF shares in Q1 2023, an estimated $201K.
  • EFG Asset Management (Americas) first reported a position in iShares Biotechnology ETF in Q4 2014 and held it in 9 quarters.
  • EFG Asset Management (Americas)'s iShares Biotechnology ETF position peaked at $249K in Q2 2021.
  • 866 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2023.

Based on EFG Asset Management (Americas)'s 13F filing for Q1 2023, filed 4 May 2023.